|
|
||||||||
FORUM |
From the Daiichi Medical Research, London, United Kingdom (Dr Darpo); the Department of Cardiology, Karolinska Hospital, Stockholm, Sweden (Dr Darpo); the Medical Sciences, Institut de Recherches Internationales SERVIER, Paris, France (Dr Nebout); Cardiovascular Research, AstraZeneca LP, Wilmington, Delaware (Dr Sager); and the University of Medicine and Dentistry of New Jersey, Newark, New Jersey (Dr Sager).
Proarrhythmias due to drug-induced QT prolongation are the second most common cause for drug withdrawal and have caused increasing concern. Two new International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines were recently endorsed in which nonclinical (S7B) and clinical (E14) methodologies are discussed and guidance is given to the industry. This commentary describes the key components of the E14 document, the impact of nonclinical testing on the clinical program, the thorough QT study, and the impact of its result on late-stage development. The studies described in S7B and E14 will contribute to a better understanding of the link between nonclinical assays and QT prolongation in humans. Differences in interpretation among individual regulators in the major regions with respect to measures proposed in the E14 guideline might impact regional regulatory decisions. These differences include the value of nonclinical assays for the subsequent clinical testing and how predictive a negative thorough QT study result is for proarrhythmic risk in patients.
Key Words: QT prolongation ICH E14 thorough QT study ECG methodology
Address for reprints: Borje Darpo, MD, PhD, Daiichi Medical Research, 76 Shoe Lane, London EC4A 3JB United Kingdom; e-mail: borje.darpo{at}dmr.daiichius.com.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
N. Sarapa, S. F. Francom, S. M. Azzam, P. K. Wickremasingha, and B. Tyl Detection of Clinically Significant QTc Prolongation in Phase I Studies in Healthy Participants: Comparison of 2 Semiautomated QT Measurement Methods J. Clin. Pharmacol., January 1, 2009; 49(1): 103 - 108. [Full Text] [PDF] |
||||
![]() |
M. Peeters, K. Janssen, T. N Kakuda, M. Scholler-Gyure, R. Lachaert, R. M. Hoetelmans, B. Woodfall, and G. De Smedt Etravirine Has No Effect on QT and Corrected QT Interval in HIV-Negative Volunteers Ann. Pharmacother., June 1, 2008; 42(6): 757 - 765. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Hutmacher, S. Chapel, M. A. Agin, J. C. Fleishaker, and R. L. Lalonde Performance Characteristics for Some Typical QT Study Designs Under the ICH E-14 Guidance J. Clin. Pharmacol., February 1, 2008; 48(2): 215 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Roden, P. Kannankeril, and D. Darbar On the relationship among QT interval, atrial fibrillation, and torsade de pointes Europace, September 1, 2007; 9(suppl_4): iv1 - iv3. [Full Text] [PDF] |
||||
![]() |
B. Darpo Detection and reporting of drug-induced proarrhythmias: room for improvement Europace, September 1, 2007; 9(suppl_4): iv23 - iv36. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |